Skip to content

PP&E (Net) at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$7.66B+6.2%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
$3.2M-42.4%
Corvus Pharmaceuticals logo
Corvus PharmaceuticalsCRVS
$282K+70.9%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$112.79M-16.6%
Janux Therapeutics logo
Janux TherapeuticsJANX
$3.55M-28.3%

Other financials

Income statement

See full
Revenue-
Net income-$7.5M-13.1%
EPS (diluted)-$0.13+13.3%

Balance sheet

See full
Cash & equivalents$6.3M+1.3%
Total debt$456.9K+178%
Total equity$23.2M+135%
Total assets$29.7M+103%

Cash flow

See full
Operating cash flow-$4.4M+6.9%
CapEx$48.8K+14.5%
Free cash flow-$4.5M+6.7%

Valuation

See full
Market cap$155.39M+45.8%
Enterprise value$149.54M+52.3%

Returns & leverage

See full
Return on equity-187.2%
Debt / equity0.0×
Current ratio1.2×-1.8×

Where this comes from

Reported directly by TuHURA Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.

The official record: TuHURA Biosciences, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about TuHURA Biosciences, Inc.'s pp&e (net).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is TuHURA Biosciences, Inc.'s PP&E (net)?
TuHURA Biosciences, Inc. (HURA) reported PP&E (net) of $326.01K in Q1 2026.
How has TuHURA Biosciences, Inc.'s PP&E (net) changed year-over-year?
TuHURA Biosciences, Inc.'s PP&E (net) increased by 114.5% year-over-year, from $151.98K to $326.01K.
What is the long-term trend for TuHURA Biosciences, Inc.'s PP&E (net)?
Over 3 years (2022 to 2025), TuHURA Biosciences, Inc.'s PP&E (net) has grown at a -25.9% compound annual growth rate (CAGR), from $739K to $300.64K.
What does PP&E (net) mean?
Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.